Literature DB >> 22736911

New perspectives in occult hepatitis C virus infection.

Vicente Carreño, Javier Bartolomé, Inmaculada Castillo, Juan Antonio Quiroga.   

Abstract

Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.

Entities:  

Keywords:  Hepatitis C virus RNA; Liver; Occult hepatitis C virus; Peripheral blood mononuclear cells; T-cell response

Mesh:

Substances:

Year:  2012        PMID: 22736911      PMCID: PMC3380315          DOI: 10.3748/wjg.v18.i23.2887

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  66 in total

1.  Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope.

Authors:  Juan A Quiroga; Inmaculada Castillo; Silvia Llorente; Javier Bartolomé; Guillermina Barril; Vicente Carreño
Journal:  J Hepatol       Date:  2008-11-04       Impact factor: 25.083

2.  Occult hepatitis C virus infection among hemodialysis patients.

Authors:  Guillermina Barril; Inmaculada Castillo; María Dolores Arenas; Mario Espinosa; Juan Garcia-Valdecasas; Nuria Garcia-Fernández; Emilio González-Parra; José María Alcazar; Carmen Sánchez; José Carlos Diez-Baylón; Pilar Martinez; Javier Bartolomé; Vicente Carreño
Journal:  J Am Soc Nephrol       Date:  2008-08-06       Impact factor: 10.121

3.  Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles.

Authors:  T N Q Pham; S E Mercer; T I Michalak
Journal:  J Viral Hepat       Date:  2009-02-08       Impact factor: 3.728

4.  Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV.

Authors:  Eishiro Mizukoshi; Christoph Eisenbach; Brian R Edlin; Kimberly P Newton; Sukanya Raghuraman; Christina Weiler-Normann; Leslie H Tobler; Michael P Busch; Mary Carrington; Jane A McKeating; Thomas R O'Brien; Barbara Rehermann
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

5.  Hepatitis C virus infection in the family setting of patients with occult hepatitis C.

Authors:  Inmaculada Castillo; Javier Bartolomé; Juan Antonio Quiroga; Guillermina Barril; Vicente Carreño
Journal:  J Med Virol       Date:  2009-07       Impact factor: 2.327

6.  Immune suppression leading to hepatitis C virus re-emergence after sustained virological response.

Authors:  Amy Lin; Anupama Thadareddy; Michael J Goldstein; Gerond Lake-Bakaar
Journal:  J Med Virol       Date:  2008-10       Impact factor: 2.327

7.  Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users.

Authors:  M Zeremski; M A Shu; Q Brown; Y Wu; D C Des Jarlais; M P Busch; A H Talal; B R Edlin
Journal:  J Viral Hepat       Date:  2008-07-17       Impact factor: 3.728

8.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

9.  Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection.

Authors:  I Castillo; J Bartolomé; J A Quiroga; G Barril; V Carreño
Journal:  Aliment Pharmacol Ther       Date:  2009-06-11       Impact factor: 8.171

10.  Occult HCV infection: an unexpected finding in a population unselected for hepatic disease.

Authors:  Laura De Marco; Anna Gillio-Tos; Valentina Fiano; Guglielmo Ronco; Vittorio Krogh; Domenico Palli; Salvatore Panico; Rosario Tumino; Paolo Vineis; Franco Merletti; Lorenzo Richiardi; Carlotta Sacerdote
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more
  25 in total

Review 1.  Epidemiology of hepatitis C virus in Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 2.  Hepatitis C virus: A time for decisions. Who should be treated and when?

Authors:  Bashar M Attar; David H Van Thiel
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

3.  Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta university hospitals: a single-center study.

Authors:  Ghada Abdelmoemen; Samy Abdelkader Khodeir; Sabry Abou-Saif; Abdelrahman Kobtan; Sherief Abd-Elsalam
Journal:  Environ Sci Pollut Res Int       Date:  2017-12-06       Impact factor: 4.223

4.  Natural history of vertically acquired HCV infection and associated autoimmune phenomena.

Authors:  Silvia Garazzino; Carmelina Calitri; Antonella Versace; Alda Alfarano; Carlo Scolfaro; Chiara Bertaina; Simona Vatrano; Federica Mignone; Francesco Licciardi; Clara Gabiano; Pier-Angelo Tovo
Journal:  Eur J Pediatr       Date:  2014-03-04       Impact factor: 3.183

Review 5.  Management of hepatitis C virus infection in hemodialysis patients.

Authors:  Yue-Cheng Yu; Yue Wang; Chang-Lun He; Mao-Rong Wang; Yu-Ming Wang
Journal:  World J Hepatol       Date:  2014-06-27

6.  Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma.

Authors:  Brenda Y Hernandez; Xuemei Zhu; Sandi Kwee; Owen T M Chan; Naoky Tsai; Gordon Okimoto; David Horio; Katherine A McGlynn; Sean Altekruse; Linda L Wong
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-08-27       Impact factor: 4.254

Review 7.  Enzyme-linked immunosorbent/chemiluminescence assays, recombinant immunoblot assays and nucleic acid tests in the diagnosis of HCV infection.

Authors:  Robério Amorim de Almeida Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-11       Impact factor: 3.267

8.  Detection of hepatitis C virus (HCV) RNA in the peripheral blood mononuclear cells of HCV-infected patients following sustained virologic response.

Authors:  Mahmoud A Khattab; Yehia Zakaria; Eslam Sadek; Aliaa S Abd El Fatah; Magdy Fouad; Muhammed Khattab; Hend M Moness; Nashwa Mohamed Adel; Elham Ahmed
Journal:  Clin Exp Med       Date:  2022-01-23       Impact factor: 3.984

Review 9.  Chronic HCV infection: epidemiological and clinical relevance.

Authors:  S Zaltron; A Spinetti; L Biasi; C Baiguera; F Castelli
Journal:  BMC Infect Dis       Date:  2012-11-12       Impact factor: 3.090

10.  Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis.

Authors:  Hossein Keyvani; Farah Bokharaei-Salim; Seyed Hamidreza Monavari; Maryam Esghaei; Mohssen Nassiri Toosi; Shahin Fakhim; Zohreh Azita Sadigh; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2013-08-05       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.